Evidence map›Paper›PMID 34100731›Full record

ArticleAnatolian journal of cardiology2021

How does severe functional mitral regurgitation redefined by European guidelines affect pulmonary vascular resistance and hemodynamics in heart transplant candidates?

Zübeyde Bayram, Cem Doğan, Rezzan Deniz Acar, Süleyman Efe, Özgür Yaşar Akbal, Fatih Yılmaz, Büşra Güvendi Şengör, Ahmet Karaduman, Samet Uysal, Ali Karagöz and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Anatolian journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Zübeyde BayramDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Cem DoğanDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Rezzan Deniz AcarDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Süleyman EfeDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Özgür Yaşar AkbalDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Fatih YılmazDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Büşra Güvendi ŞengörDepartment of Cardiology, İstanbul Maltepe State Hospital; İstanbul-Turkey.
Ahmet KaradumanDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Samet UysalDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Ali KaragözDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Çağatay ÖnalDepartment of Cardiology, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital; İstanbul-Turkey.
Mehmet Kaan KıraliDepartment of Cardiovascular Surgery, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Cihangir KaymazDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Nihal ÖzdemirDepartment of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital; İstanbul-Turkey.
Kartal Koşuyolu High Specialization Training and Research Hospital · TRIstanbul Eye Hospital · TRYedikule Teaching Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIncreased pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) are important prognostic factors in patients with heart transplantation (HT). It is well known that severe mitral regurgitation increases pulmonary pressures. However, the European Society of Cardiology and the 6th World Symposium of pulmonary hypertension (PH) task force redefined severe functional mitral regurgitation (FMR) and PH, respectively. We aimed to investigate the effect of severe FMR on PAP and PVR based on these major redefinitions in patients with HT.

methodsA total of 212 patients with HT were divided into 2 groups: those with severe FMR (n=70) and without severe FMR (n=142). Severe FMR was defined as effective orifice regurgitation area ≥20 mm2 and regurgitation volume ≥30 mL where the mitral valve was morphologically normal. A mean PAP of >20 mm Hg was accepted as PH. Patients with left ventricular ejection fraction ≤25% were included in the study.

resultsThe systolic PAP, mean PAP, and PVR were higher in patients with severe FMR than in those without severe FMR [58.5 (48.0-70.2) versus 45.0 (36.0-64.0), p<0.001; 38.0 (30.2-46.6) versus 31.0 (23.0-39.5), p=0.004; 4.0 (2.3-6.8) versus 2.6 (1.2-4.3), p=0.001, respectively]. Univariate analysis revealed that the severe FMR is a risk factor for PVR ≥3 and 5 WU [odds ratio (OR): 2.0, 95% confidence interval (CI): 1.1-3.6, p=0.009; and OR: 3.2, 95% CI: 1.5-6.7, p=0.002]. The multivariate regression analysis results revealed that presence of severe FMR is an independent risk factor for PVR ≥3 WU and presence of combined pre-post-capillary PH (OR: 2.23, 95% CI: 1.30-3.82, p=0.003 and OR: 2.30, 95% CI: 1.25-4.26, p=0.008).

conclusionEven in the updated definition of FMR with a lower threshold, severe FMR is associated with higher PVR, systolic PAP, and mean PAP and appears to have an unfavorable effect on pulmonary hemodynamics in patients with HT.

Indexed as

Heart TransplantationMitral Valve InsufficiencyHemodynamicsHumansStroke VolumeVascular ResistanceVentricular Function, Left

Identifiers

PMID34100731
PMCPMC8210935
OpenAlexW3166276002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.